EANS-News: Intercell AG / Intercell starts the second part of a Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

Wien (euro adhoc) - - » Trial in vaccine target group of elderly
subjects (elderly >65 years) initiated » First data from Phase I
clinical trial showed good safety and immunogenicity of the vaccine
candidate against Clostridium difficile, the major cause of
nosocomial diarrhea, in healthy young adults » Study aims to obtain
safety and immunogenicity data in elderly subjects with results
expected in Q2 2013

Vienna (Austria), March 1, 2012 - Intercell AG (VSE: ICLL) today
announced the start of the second half of a Phase I clinical trial
with the company's vaccine candidate IC84 to prevent disease caused
by the bacterium Clostridium difficile (C. difficile).

First data from the Phase I study (Phase Ia) in a population of
healthy adults aged 18-65 years showed good safety and immunogenicity
of the vaccine candidate, and indicated functionality of induced
antibodies in this study population. This supported the decision to
carry forward the vaccine candidate for safety and dose-confirmation
in the elderly.

The second part of the Phase I study (Phase Ib) will enroll 80
healthy elderly subjects above 65 years of age, as this age group
represents the main target population for a C. difficile vaccine. Two
vaccine concentrations will be tested with and without alum to
confirm the vaccine dose and necessity of the adjuvant in the
elderly. Compared to the Phase Ia part of the study in healthy young
adults, the vaccination schedule has been modified to potentially
optimize the immune response in elderly subjects who might respond
differently to the vaccination due to their immunosenescence.

Intercell's vaccine candidate is a recombinant fusion protein
consisting of two truncated toxins A and B from C. difficile. The
toxins are known to be disease-causing and anti-toxin immunity can be
protective.

The pathogen C. difficile is one of the main causes of nosocomial
diarrhea.

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English